Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Frazão, João M ^a   Braun, Johann ^b   Messa, Piergiorgio ^c   Dehmel, Bastian ^d   Mattin, Caroline ^e   Wilkie, Martin ^f  

^a UNIVERSITY OF PORTO   (Portugal)

^b KHz Kuratorium fur Dialyse und Nieren Transplantation   (Germany)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d AMGEN INC   (United States)

^e AMGEN LTD   (United Kingdom)

^f SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALUMINUM; CALCITRIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CAUSALITY; COMORBIDITY; DIALYSIS; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PREVALENCE; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84867552878     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-76     Document Type: Article

References (38)

1. Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, Brown A, Dusso A, Kidney Intl 1999 73 14 19
2. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Intl 2006 69 11 1945 1953 10.1038/sj.ki.5000414 (Pubitemid 43924257)
3. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Am J Kidney Dis 1998 31 4 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176
4. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 8 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
5. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK, J Am Soc Nephrol 2001 12 10 2131 2138 11562412 (Pubitemid 32880350)
6. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RLRobinson BM, Port FK, Am J Kidney Dis 2008 52 3 519 530 10.1053/j.ajkd.2008.03.020 18514987
7. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK, Kidney Intl 2005 67 3 1179 1187 10.1111/j.1523-1755.2005.00185.x (Pubitemid 41623345)
8. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 4 Suppl 3 1 201 14655174
9. Phosphate regulation of vascular smooth muscle cell calcification. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM, Circulation Res 2000 87 7 10 17 10.1161/01.RES.87.7.e10 11009570
10. Phosphate-the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Kanbay M, Goldsmith D, Akcay A, Covic A, Blood Purif 2009 27 2 220 230 10.1159/000197562 19176951
11. The mechanism of phosphorus as a cardiovascular risk factor in CKD. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA, J Am Soc Nephrol 2008 19 6 1092 1105 10.1681/ASN.2007070760 18417722
12. Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Disease K, Kidney Intl 2009 76 suppl. 113 1 S130
13. Parathyroid Hyperplasia in Rabbits Produced by Parenteral Phosphate Administration. Drake TG, Albright F, Castleman B, J Clin Invest 1937 16 2 203 206 10.1172/JCI100848 16694469
14. Bone Resorption in Tissue Culture. Factors Influencing the Response to Parathyroid Hormone. Raisz LG, J Clin Invest 1965 44 103 116 10.1172/JCI105117 14254246
15. Hyperphosphatemia of chronic kidney disease. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R, Kidney Intl 2008 74 2 148 157 10.1038/ki.2008.130 (Pubitemid 351915080)
16. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S, Am J Kidney Dis 2010 55 5 773 799 10.1053/j.ajkd.2010. 02.340 20363541
17. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Moe SM, Drueke TB, AmJ Nephrol 2003 23 6 369 379 10.1159/000073945 (Pubitemid 37465098)
18. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millan I, Amoedo ML, Muray S, Carreton MA, Nephrol Dial Transplant 2006 21 6 1663 1668 10.1093/ndt/gfl006 16464885 (Pubitemid 43834646)
19. Consistent control of mineral and bone disorder in incident hemodialysis patients. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ, Clin J Am Soc Nephrol 2008 3 5 1423 1429 10.2215/CJN.01060308 18596117
20. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M, Am J Kidney Dis 2004 44 5 Suppl 3 34 38 15486872
21. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF, Proc Nat Acad Sci USA 1998 95 7 4040 4045 10.1073/pnas.95.7.4040 9520489 (Pubitemid 28173250)
22. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW, J Am Soc Nephrol 2002 13 4 1017 1024 11912261 (Pubitemid 34274098)
23. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG, New Engl J Med 2004 350 15 1516 1525 10.1056/NEJMoa031633 15071126 (Pubitemid 38477776)
24. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA, J Am Soc Nephrol 2003 14 3 575 583 10.1097/01.ASN.0000050224.03126.AD 12595492 (Pubitemid 36246000)
25. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW, J Am Soc Nephrol 2005 16 3 800 807 10.1681/ASN.2004060512 15689407 (Pubitemid 41725117)
26. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, Von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F, Clin J Am Soc Nephrol 2008 3 1 36 45 10.2215/CJN.03591006 18178780
27. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA, Kidney Int 2005 68 3 1236 1243 10.1111/j.1523-1755.2005.00517.x 16105056 (Pubitemid 43246442)
28. Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Peters BS, Moyses RM, Jorgetti V, Martini LA, Int Urol Nephrol 2007 39 4 1251 1256 10.1007/s11255-007-9254-2 17680337 (Pubitemid 350193624)
29. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F, Nephrol Dial Transplant 2008 23 7 2319 2323 10.1093/ndt/gfm931 18281320 (Pubitemid 351957582)
30. Dynamics of parathyroid hormone secretion after total parathyroidectomy and autotransplantation. Conti-Freitas LC, Foss-Freitas MC, Lucca LJ, da Costa JA, Mamede RC, Foss MC, World J Surg 2009 33 7 1403 1407 10.1007/s00268-009- 0057-8 19404704
31. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Juppner H, Salusky IB, J Clin Endocrinol Metab 2010 95 6 2772 2780 10.1210/jc.2009-1909 20382692
32. [SA-PO2403] Exploring the Relationship between Temporal Trends in PTH, P and Ca in HD Patients. Kilpatrick RD, Gill KS, Block GA, [abstract presented at the American Society of Nephrology Annual Meeting Denver, Colorado, November 16-21, 2010]
33. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S, Am J Nephrol 2009 29 3 230 236 10.1159/000156717 18797166
34. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB, Kidney Int 2008 73 6 771 777 10.1038/sj.ki.5002769 18185506 (Pubitemid 351323258)
35. Fracture risk after parathyroidectomy among chronic hemodialysis patients. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B, J Am Soc Nephrol 2007 18 8 2401 2407 10.1681/ASN.2007010022 17634437 (Pubitemid 47203856)
36. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin JL, Rodriguez-Puyol D, Cannata-Andia JB, Nephrol Dial Transplant 2011 26 6 1938 47 10.1093/ndt/gfq304 20513773
37. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, Nephrol Dial Transplant 2010 26 6 1948 55 20466670
38. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM, Nephrol Dial Transplant 2010 25 6 1916 1923 10.1093/ndt/gfp762 20110249